#JPM24: Madrigal says it’s ‘well on the way’ to potential NASH launch ahead of FDA decision

SAN FRANCISCO — Madrigal Pharmaceuticals will be “ready to go” if the FDA grants its nonalcoholic steatohepatitis hopeful an accelerated approval in March, the company’s new CEO Bill Sibold said Wednesday.

Resmetirom would be the first approved treatment in an area that’s seen failure after failure, including Intercept’s closely watched…
Click here to view original post